Literature DB >> 25711339

Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.

Kyunghee Yang1, Nathan D Pfeifer1, Kathleen Köck1, Kim L R Brouwer2.   

Abstract

The bile salt export pump (BSEP) plays an important role in bile acid excretion. Impaired BSEP function may result in liver injury. Bile acids also undergo basolateral efflux, but the relative contributions of biliary (CLBile) versus basolateral efflux (CLBL) clearance to hepatocellular bile acid excretion have not been determined. In the present study, taurocholic acid (TCA; a model bile acid) disposition was characterized in human and rat sandwich-cultured hepatocytes (SCH) combined with pharmacokinetic modeling. In human SCH, biliary excretion of TCA predominated (CLBile = 0.14 ± 0.04 ml/min per g liver; CLBL = 0.042 ± 0.019 ml/min per g liver), whereas CLBile and CLBL contributed approximately equally to TCA hepatocellular excretion in rat SCH (CLBile = 0.34 ± 0.07 ml/min per g liver; CLBL = 0.26 ± 0.07 ml/min per g liver). Troglitazone decreased TCA uptake, CLBile, and CLBL; membrane vesicle assays revealed for the first time that the major metabolite, troglitazone sulfate, was a noncompetitive inhibitor of multidrug resistance-associated protein 4, a basolateral bile acid efflux transporter. Simulations revealed that decreased CLBile led to a greater increase in hepatic TCA exposure in human than in rat SCH. A decrease in both excretory pathways (CLBile and CLBL) exponentially increased hepatic TCA in both species, suggesting that 1) drugs that inhibit both pathways may have a greater risk for hepatotoxicity, and 2) impaired function of an alternate excretory pathway may predispose patients to hepatotoxicity when drugs that inhibit one pathway are administered. Simulations confirmed the protective role of uptake inhibition, suggesting that a drug's inhibitory effects on bile acid uptake also should be considered when evaluating hepatotoxic potential. Overall, the current study precisely characterized basolateral efflux of TCA, revealed species differences in hepatocellular TCA efflux pathways, and provided insights about altered hepatic bile acid exposure when multiple transport pathways are impaired.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25711339      PMCID: PMC4407722          DOI: 10.1124/jpet.114.221564

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  41 in total

Review 1.  Cultured rat hepatocytes.

Authors:  E L LeCluyse; P L Bullock; A Parkinson; J H Hochman
Journal:  Pharm Biotechnol       Date:  1996

2.  Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements.

Authors:  Anna-Karin Sohlenius-Sternbeck
Journal:  Toxicol In Vitro       Date:  2006-06-29       Impact factor: 3.500

3.  Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.

Authors:  P L Jansen; S S Strautnieks; E Jacquemin; M Hadchouel; E M Sokal; G J Hooiveld; J H Koning; A De Jager-Krikken; F Kuipers; F Stellaard; C M Bijleveld; A Gouw; H Van Goor; R J Thompson; M Müller
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

4.  Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.

Authors:  Elaine M Leslie; Paul B Watkins; Richard B Kim; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2007-03-20       Impact factor: 4.030

5.  Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes.

Authors:  Eskouhie H Tchaparian; Jessica S Houghton; Craig Uyeda; Mark P Grillo; Lixia Jin
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

6.  Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

Authors:  Maria Rius; Johanna Hummel-Eisenbeiss; Alan F Hofmann; Dietrich Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-11-10       Impact factor: 4.052

7.  Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver.

Authors:  H Akita; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

Authors:  Ryan E Morgan; Michael Trauner; Carlo J van Staden; Paul H Lee; Bharath Ramachandran; Michael Eschenberg; Cynthia A Afshari; Charles W Qualls; Ruth Lightfoot-Dunn; Hisham K Hamadeh
Journal:  Toxicol Sci       Date:  2010-09-09       Impact factor: 4.849

Review 9.  Bile acids: regulation of synthesis.

Authors:  John Y L Chiang
Journal:  J Lipid Res       Date:  2009-04-03       Impact factor: 5.922

10.  Motility of bile canaliculi in the living animal: implications for bile flow.

Authors:  N Watanabe; N Tsukada; C R Smith; M J Phillips
Journal:  J Cell Biol       Date:  1991-06       Impact factor: 10.539

View more
  22 in total

Review 1.  Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.

Authors:  David J Hughes; Tomasz Kostrzewski; Emma L Sceats
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-15

Review 2.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

3.  Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.

Authors:  Melina M Malinen; Izna Ali; Jacqueline Bezençon; James J Beaudoin; Kim L R Brouwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-02-08       Impact factor: 4.052

Review 4.  In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Authors:  Shannon M Bell; Xiaoqing Chang; John F Wambaugh; David G Allen; Mike Bartels; Kim L R Brouwer; Warren M Casey; Neepa Choksi; Stephen S Ferguson; Grazyna Fraczkiewicz; Annie M Jarabek; Alice Ke; Annie Lumen; Scott G Lynn; Alicia Paini; Paul S Price; Caroline Ring; Ted W Simon; Nisha S Sipes; Catherine S Sprankle; Judy Strickland; John Troutman; Barbara A Wetmore; Nicole C Kleinstreuer
Journal:  Toxicol In Vitro       Date:  2017-12-05       Impact factor: 3.500

5.  Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.

Authors:  Cen Guo; Kyunghee Yang; Kenneth R Brouwer; Robert L St Claire; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2016-05-27       Impact factor: 4.030

Review 6.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

7.  Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.

Authors:  Hee Eun Kang; Melina M Malinen; Chitra Saran; Paavo Honkakoski; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

8.  Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β).

Authors:  Melina M Malinen; Antti Kauttonen; James J Beaudoin; Noora Sjöstedt; Paavo Honkakoski; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2018-12-14       Impact factor: 4.939

Review 9.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

10.  Mechanistic Modeling of the Hepatic Disposition of Estradiol-17β-Glucuronide in Sandwich-Cultured Human Hepatocytes.

Authors:  Katsuaki Ito; Noora Sjöstedt; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-11-19       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.